Everything below concerns peptide analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Platforms == Current nanoparticle drug delivery systems can be cataloged based on their platform composition into several groups: polymeric nanoparticles, inorganic nanoparticles, viral nanoparticles, lipid-based nanoparticles, and nanoparticle albumin-bound (nab) technology. Each family has its unique characteristics.
Pharmacokinetics (from Ancient Greek pharmakon 'drug' and kinetikos 'moving, putting in motion'; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific substance after administration. The substances of interest include any chemical xenobiotics such as pharmaceutical drugs, pesticides, food additives, cosmetics, etc. PK attempts to analyze chemical metabolism and discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. PK is based on mathematical modeling that places great emphasis on the relationship between drug plasma concentration and the time elapsed since the drug's administration. Pharmacokinetics is the study of how an organism affects the drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.
The unattended and remote nature of many data logger applications implies the need for some applications to operate from a DC power source, such as a battery. Solar power may be used to supplement these power sources. These constraints have generally led to ensuring that the devices they market are extremely power efficient relative to computers. In many cases, they are required to operate in harsh environmental conditions where computers will not function reliably. This unattended nature also dictates that data loggers must be extremely reliable. Since they may operate for long periods nonstop with little or no human supervision and may be installed in harsh or remote locations, it is imperative that so long as they have power, they will not fail to log data for any reason. Manufacturers go to great lengths to ensure that the devices can be depended on in these applications. As such data loggers are almost completely immune to the problems that might affect a general-purpose computer in the same application, such as program crashes and the instability of some operating systems.
Sources: en.wikipedia.org
The trial judge did not accept this defence, noting that comments such as Galloway being guilty of "treason", "in Saddam's pay", and being "Saddam's little helper" caused him [the judge] to conclude that "the newspaper was not neutral but both embraced the allegations with relish and fervour and went on to embellish them"; additionally, the judge ruled, Galloway had not been given a fair or reasonable opportunity to make inquiries or meaningful comment upon the documents before they were published.
Isaria cicadae Miq. 1838, which is the same as Cordyceps cicadae (Miq.) Massee 1895 and Paecilomyces cicadae. The preferred name for this species appears to be Cordyceps cicadae (Miq.) Massee 1895, especially since Isaria has proven to be polyphyletic. Cordyceps cicadae Shing 1975, which is now properly known as Tolypocladium dujiaolongae Y.P. Cao & C.R. Li after its local name in TCM ("Du Jiao Long"). Some Chinese sources believe that it is the teleomorph of "Chan Hua", which is now proven false with the discovery of its true teleomorph. Cordyceps sobolifera (now Ophiocordyceps sobolifera). Japanese sources incorrectly believe that this is the teleomorph of "Chan Hua", but it is in reality another TCM material known as "Xiao Chan Hua" (small cicada flower). The error has spread to Korean, Taiwanese, and Chinese sources. Cordyceps kobayasii, another purported teleomorph of "Chan Hua". Cordyceps chanhua Z.Z. Li et al., which is the correct name of "Chan Hua". In traditional medicine-related papers, each of the names have been used to describe the material known as "Chan Hua". C. cicadae and I. cicadae used to be very common in sources written by Chinese researchers, though they have largely adopted the corrected C. chanhua name. Japanese, Korean, and Taiwanese sources still use C. sobolifera. Other reported synonyms include Cordyceps zhejiangensis and C. sinclairii.
=== Aging and diseases associated with aging === α-Ketoglutarate has been reported to increase the life span and/or delay the development of old age-related diseases in a species of roundworms and in mice. It nearly doubled the life span and delayed age-related deteriorations (e.g., decline in rapid, coordinated body movements) of Caenorhabditis elegans roundworms when added to their cell cultures. Similarly, mice fed a diet high in calcium-bound α-ketoglutarate had a longer life span and shorter length of time in which they suffered old age-related morbidities (e.g., increased frailty, hair loss, and changes in body weight). Cell cultures of splenocytes (i.e., primarily T cells) from the α-ketoglutarate-fed mice produced higher levels of the anti-inflammatory cytokine, interleukin-10, than splenocytes from mice not fed α-ketoglutarate. (Chronic low-grade inflammation which might be inhibited by interleukin-10, is associated with the development of old age-related disorders and diseases.) As individuals age, their DNA develops additions of a methyl group (-CH3) to a cytosine adjacent to a guanine (termed a CpG island) in an increasing number of CpG islands close to certain genes. These methylations often suppress the expression of the genes to which they are close. Assays (termed epigenetic clock tests) that determine the presence of methylations of cytosine in CpG islands for genes have been used to define an individual's biological age.
Sources: en.wikipedia.org
24 March – Avanti West Coast is to increase the fee for an overtime shift for its drivers by 380% following a deal with train drivers' union ASLEF. 26 March Pizza retailer Papa John's announces the closure of 43 of its 450 UK outlets. The High Court of Justice grants WikiLeaks founder Julian Assange a stay of extradition to the United States, and demands that the US not consider the death penalty against Assange if he is sent to the US to face espionage charges. 27 March – Provisional figures from the Home Office indicate that 4,644 migrants have crossed the English Channel in boats during the first three months of 2024. 28 March – BBC News publishes details of a 2016 draft report that implies the Post Office knew its defence case in the Horizon IT scandal was false, and that it had not made full disclosure to defendants. 29 March Sir Jeffrey Donaldson resigns as leader of the Democratic Unionist Party after being charged with rape and other historical sexual offences. Gavin Robinson is appointed interim leader until a new leader can be elected. Pouria Zeraati, an anti-Iranian regime journalist working for Iran International, is stabbed by a group of people in London. He is taken to hospital, where he is in stable condition. 30 March First Minister of Northern Ireland Michelle O'Neill says she is determined the Stormont Assembly and Executive will continue to function following the resignation of Jeffrey Donaldson as DUP leader.
=== Vaccine skepticism and connection to autism === In 2009, Carrey wrote an article questioning the merits of vaccination and discussing its connection to autism for The Huffington Post. With former partner Jenny McCarthy, Carrey led a "Green Our Vaccines" march in Washington, D.C., to advocate for the removal of "toxic substances" from children's vaccines, out of a belief that children had received "too many vaccines, too soon, many of which are toxic". The rally was criticized by David Gorski, an American surgical oncologist on Science-Based Medicine blog, for being anti-vaccine and not "pro-safe vaccine", and by Steven Parker on the WebMD website for being "irresponsible". In 2009, the couple appeared on Larry King Live to discuss autism. Carrey stated that he believes autism "is preventable and treatable," and that "it's still shocking to see how many people are ignoring this information." Carrey suggested rising autism rates was a warning about the medical industry, stating: "There's an autistic child on every block ... Autism is the canary in the coal mine. I believe that it's telling us that this vaccine program is imbalanced." On July 1, 2015, after the signing of a new vaccination law, Carrey called California governor Jerry Brown a "corporate fascist" who was "poisoning" children by enacting the vaccination requirements. The law disallowed religious and philosophical reasons for exemption from vaccination.
=== Period 1: Initial transitional style === The first period consist in a short interval of transitional style, in which paintings remain subtil and rather nuanced, but blue pigments have started to appear. The Cave of the Devil C (Cave 198) and Cave of the Devil A (Cave 199), as well as the Cave with the Steps (Cave 110) and sometimes the Red-domed Cave A (Cave 67) are considered as the first period of this new style.
Those who report a false claim against the federal government, and suffer adverse employment actions as a result, may have up to six years (depending on state law) to file a civil suit for remedies under the US False Claims Act (FCA). Under a qui tam provision, the "source" for the report may be entitled to a percentage of what the government recovers from the offenders. However, the "source" must also be the first to file a federal civil complaint for recovery of the federal funds fraudulently obtained, and must avoid publicizing the claim of fraud until the US Justice Department decides whether to prosecute the claim itself. Such qui tam lawsuits must be filed under seal, using special procedures to keep the claim from becoming public until the federal government makes its decision on direct prosecution. Whistleblowers acting under the FCA are the primary enforcement tool used by the U.S. Department of Justice to target fraud, including overbilling to government programs like Medicare, Medicaid, and Tricare.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.